QIAGEN二季度业绩小幅超公司展望但维持全年指引不变

Qiagen N.V. - QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
Skip to main content
Products
Applications & Insights
Knowledge & Support
About QIAGEN
My QIAGEN
Quick Order
Cart
Site Search
Close Search
Search query
Discovery
& Translational Research
Diagnostics
& Clinical Research
Human ID &
Forensics
Next-Generation
Sequencing
Instruments &
Automation
Informatics & Data
OEM by QIAGEN
COVID-19
Top Sellers
Shop
DNA & RNA
Purification
Protein Purification
Exosomes & CTCs
Sample
Collection & Stabilization
PCR/qPCR/dPCR
Custom LNA
Oligonucleotides
Pyrosequencing
ISH & Northern
Blotting
Epigenetics
Functional &
Cell Analysis
Lab Essentials
GeneGlobe
Design & Analysis Hub
RNeasy Mini Kit
High-quality total RNA in minutes.
TB Management
QuantiFERON-TB Gold Plus
Transplant
QuantiFERON Transplant
artus
Viral Load
Infectious
Disease
QIAstat-Dx Syndromic Testing
Oncology
therascreen Solid Tumor
ipsogen
Leukemia
Circulating Tumor Cells
Sexual & Reproductive Health
Cervical Cancer Screening
Maternal/Fetal Testing
STI
Testing
Processing
Solutions for Laboratory-Developed
Tests
Sample Collection
Investigator
Solutions
Human DNA
Quantification
STR Technology
Next-Generation Sequencing
Investigator 24plex QS Kit
Multiplex amplification for human ID, with CODIS and European standard markers.
GeneReader NGS System
Nucleic Acid
PCR Instruments
PCR Setup &
Liquid Handling
Quality
Control & Fragment Analysis
Service Solutions
Accessories
Analytics Software
Automatable Kits
Tissue Disruption
QIAsphere
Monitor and manage your QIAsphere-ready instruments from anywhere, using any mobile
device.
Smart ideas, deep insights
Get inspiring content today – with a free face mask.
DNA Sequencing
RNA Sequencing
Multianalyte
Sequencing (Multimodal)
Sample Quality Control
Whole
Genome/Transcriptome Amplification
DNA Methylation
Analysis
Metagenomics
Analysis &
Visualization
Interpretation & Content Databases
Enterprise Solutions
Clinical
QIAGEN Clinical Insight (QCI) Interpret
Transparent, evidence-based NGS interpretation and reporting.
Find out more
QIAGENbioinformatics.com
OEM Reagents and
Chemistries
Point of Care
Instruments
COVID-19 testing and research
Up to date protocols and list of COVID-19 testing and research solutions.
DNA
RNA
Multianalyte &
Virus
Equipment
Crystallization
Fractionation &
Depletion
Tagged Protein Expression, Purification, Detection
Circulating Tumor
Cells
Exosomes
Tissue/FFPE
PCR Enzymes & Kits
Real-Time PCR
Enzymes & Kits
qPCR Assays &
Preamplification
dPCR Assays
Kits & Instruments
Software
Assays
Consumables
Chromosome
Conformation
Histone Modification
ELISA Assays
Gene Reporter Assays
miRNA Functional
RNA Silencing
Transfection
Buffers & Reagents
Centrifuges
Enzymes
Gel Electrophoresis
Magnets
Plastics
Vacuum
Manifolds & Accessories
QIAcube Connect Kits
QIAcube HT Kits
QIAsymphony Kits
EZ1 Kits
Whole Genome
Whole Exome Sequencing
Targeted DNA Panels
Single Cell DNA
Custom DNA Panels
3’ RNAseq
miRNA & Small
RNAseq
RNA Fusions
Stranded RNAseq
Targeted RNA Panels
T-Cell Receptor
Single Cell RNA
Ultraplex 3’
Targeted
Ribosomal
RNA & Globin mRNA Removal
Custom RNA Panels
Multimodal Panels
Single Cell DNA/RNA
Custom Multimodal
Panels
Single Cell & Low
Input
Whole Transcriptome
Targeted Metagenomics
Metatranscriptome
End-Point PCR
HiFidelity, Long-Range & Other PCR
One-Step RT-PCR
Reverse Transcription & cDNA Synthesis
Probe-Based One-Step
qRT-PCR
Probe-Based qPCR
Reverse Transcription & cDNA Synthesis for qPCR
SYBR
Green- or Dye-Based One-Step qRT-PCR
SYBR Green- or
Dye-Based qPCR
CNV qPCR Assays
& Arrays
Microbial
DNA qPCR Assays & Panels
miRNA qPCR Assay
& Panels
mRNA/IncRNA
qPCR Assays & Panels
Somatic Mutations qPCR Assays & Panels
Food Safety Testing
Preamplification Kits
REPLI-g
dPCR Instruments
dPCR Kits
dPCR Accessories
Bisulfite Conversion
Methylation-Specific
PCR
Cell-Free DNA
DNA Clean Up
Genomic DNA
Microbial DNA
Plasmid DNA
Cell-Free RNA
Microbial RNA
miRNA
mRNA
RNA Clean Up
Total RNA
Detect TB infection with confidence.
Infectious Disease
Cancer Research
Digital PCR
Molecular Biology
Research
GeneGlobe Design
& Analysis
Next-generation
sequencing
Genomic Services
Microbiome
Liquid Biopsy
Partnering
for Precision Diagnostics
Sexual &
Reproductive Health
TB
Management
Plant Research
Digital is the new absolute
Overview
Events & Webinars
Knowledge Hub
Quality & Safety
Data
Product &
Technical Support
Ordering Support
Resources
Order Support Contact
Contact
Service Agreements
QIAlab Consulting
One-Time Services
Professional Services
Bench Guide
Technology &
Explainer Videos and
Demos
Events and Webinars
Blogs
Certificate of Analysis
Safety Data Sheets
Quality Assurance
GHS Hazard Labeling
Protein Crystallization Production Reports
QIAGEN
Exclusion Database Service
Troubleshooting Guide
New Lab Start-Up
Program
Green Packaging
Web
Marketplace Solutions
Local Ordering
QIAstock
Upcoming Live Sessions
Webinars On-Demand
Animal Cell Culture
FFPE
Plasmid
Protein
Amplification
LNA Technology
HRM Technology
Plasmid Resource Center
Pyrosequencing Resource Center
Whole Genome Amplification
Oncology Companion Diagnostics
On-demand Sessions
Digital PCR Technology
Cancer –
Unraveling the Complexities
Plasmid Resource
Center
Resource Center
Reproducibility Through Automation
RNA Resource Center
Single Cell Analysis
QuantiFERON Technology
Biomarker Insights
Digital Insights
About Us
Careers
Customer Stories
Investor Relations
Newsroom
Sustainability
Compliance
Contact Us
Our Customers and Products
Our Global Presence
Our Views
Our Leadership
Who we are
Learn about who we are and what we do to make improvements in life
possible.
Why QIAGEN
Meet the QIAGENers
Your Path to QIAGEN
Find jobs
Join the QIAGEN team
Latest information on COVID-19
News, testing solutions and stories covering global efforts in the fight against
COVID-19.
Our stories
Explore our digital magazine full of customer stories and videos on scientific
breakthroughs and healthcare advances.
Market Strategy
Read our equity story, financial disclosures and how we create shareholder value.
Executive Committee
Supervisory Board
Scientific Advisory
Board
Latest News
Read up on our latest press releases or peruse our various media archives.
Environment
Employees
Society
A letter from the CEO
Report a Concern
Human Rights
Supply Chain
Order Support
Technical Questions
Human Resources
Business Development
Pharmaceutical
Industry
Media Inquiries
Contacts
Website Feedback
Global Contacts
Thank you for choosing QIAGEN. If you have questions about QIAGEN, our products or
your order, this page should help you find the answers and contacts you need.
QIAGEN Subsidiaries
Commercial Partner and Distributor Solutions
Lead Forensics Script
& RNA Purification
Cell-Free
DNA Clean
Up
Genomic
RNA Clean
Total
Tagged Protein
Expression, Purification, Detection
& CTCs
Sample Collection & Stabilization
PCR Enzymes &
Kits
End-Point
HiFidelity,
Long-Range & Other
One-Step
RT-PCR
Reverse
Transcription & cDNA
Synthesis
Real-Time PCR Enzymes
& Kits
Probe-Based
One-Step qRT-PCR
qPCR
Synthesis for qPCR
Green- or Dye-Based
CNV qPCR
Assays & Arrays
DNA qPCR Assays &
qPCR Assay &
Somatic
Mutations qPCR Assays
Food
Safety Testing
dPCR Assays Kits &
dPCR
Custom LNA Oligonucleotides
ISH
& Northern Blotting
Bisulfite
Conversion Assays
Functional & Cell Analysis
Silencing
Buffers &
Reagents
Vacuum Manifolds &
GeneGlobe Design & Analysis Hub
artus Viral
Load
STI Testing
Collection
Investigator Solutions
Human
DNA Quantification
Whole Exome
Fusions
Ultraplex 3’ Targeted
Ribosomal RNA &
Globin mRNA Removal
Multianalyte Sequencing (Multimodal)
Quality Control
Whole Genome/Transcriptome
Methylation Analysis
GeneReader
NGS System
Nucleic
Acid Purification
PCR Setup & Liquid Handling
Quality Control & Fragment
Service
Analytics
Automatable
EZ1
Tissue
Disruption
Analysis & Visualization
Interpretation & Content
Databases
Enterprise
OEM
Reagents and Chemistries
Point
of Care Instruments
Service & Support
Service Contact Center
Order
Support Contact
Technical Support Contact
Learning Hub
Stories
& Insights
Downloads
Virtual Events
Upcoming Live
Sessions
Videos
& Animations
Virtual Demos
Molecular Biology Methods
Technologies & Research Topics
Technology
Cancer – Unraveling the
Complexities
Pyrosequencing Resource
Reproducibility Through
Sample Quality
Control
QuantiFERON
Bioinformatics Blog
Certificates
GHS Hazard
Labeling
Protein Crystallization Production
Reports
Safety Data
Sheets
Assurance
QIAGEN Exclusion Database Service
Product FAQ
Troubleshooting Molecular Biology
Applications
Product
Selection Guides
Product Finder
New Lab
Start-Up Program
Green
Packaging
Ordering from QIAGEN
Web Shop
Marketplace
Commercial Partner and Distributor
Terms
& Conditions
Our Global
Presence
Our History
Executive
Committee
Supervisory
Meet the
QIAGENers
Your Path to
A letter
from the CEO
Technical
Questions
Business
Development
Pharmaceutical Industry
Media
Inquiries
Investor Relations Contacts
Website
Feedback
Global
Commercial Partner and
Distributor Solutions
Press Release
At a Glance
Equity Story
Key Figures
Strategy
Insights Magazine
Stock Information
Share Data
Share Price
Stock Quote
Stock Chart
Historical Stock Quote
Investment Calculator
Shareholder Structure
Analyst Coverage
Analyst Consensus
Share Buyback
Financials & SEC Filings
Financial Reports
Other Reports
Ad-Hoc Announcements
Directors Dealings
Annual General Meeting
Corporate Governance & ESG
Governance Documents
Leadership
Events & Presentations
Spotlight Sessions
Deep Dives
Resources & Newsroom
IR Contacts
Stock Transfer Agent
FAQs
Email Alerts
Information Request Form
Press Releases
Media kit
Video footage
Photo archive
Press Contact
Home
>
Press Release Details
View all news
Alle Neuigkeiten ansehen
Multimedia Files:
QIAGEN Exceeds Q2 2026 Outlook as Pillars Deliver Solid Sales Growth; Reaffirms Full-Year Outlook
August 5, 2026
Download
PDF Format (opens in new window)
Further Information
Weitere Informationen
Press release
PDF
Pressemitteilung
Q2 2026 results:
Net sales of $535 million unchanged compared with Q2 2025 on a reported basis and at constant exchange rates (CER), exceeding the outlook for an about 2% CER decline
Growth pillars deliver about 5% CER growth, led by Sample technologies, QIAcuity and QDI; QuantiFERON sales rise slightly amid lower U.S. immigration testing demand
Adjusted operating income margin of 29.4%, maintaining a high level of profitability
Diluted EPS of $0.50; adjusted diluted EPS of $0.62 on a reported and CER basis, above the outlook for at least $0.60 CER
H1 2026 operating cash of $301 million remains at a strong level compared with H1 2025
Full-year 2026 outlook reaffirmed for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER
VENLO, Netherlands--(BUSINESS WIRE)--
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced results for Q2 2026, with net sales and adjusted diluted earnings per share exceeding the outlook while maintaining a high level of profitability.
Net sales for Q2 2026 were unchanged at $535 million on a reported basis and at constant exchange rates (CER) compared to Q2 2025, exceeding the outlook for an approximately 2% CER decline. QIAGEN’s growth pillars together delivered 5% CER growth, led by Sample technologies delivering consumables sales growth at a high single-digit CER rate and instruments at a mid-single CER rate. QIAcuity and QIAGEN Digital Insights also delivered solid growth contributions. QuantiFERON sales rose 1% CER, reflecting the significant decline in U.S. immigration testing demand, while QIAstat-Dx sales faced a challenging prior-year comparison for respiratory testing. Adjusted diluted EPS was $0.62 on both a reported and CER basis, above the outlook for at least $0.60 CER.
QIAGEN reaffirmed its full-year 2026 outlook for net sales growth of about 1-2% CER and adjusted diluted EPS of at least $2.43 CER.
“QIAGEN delivered results above our outlook for the second quarter of 2026 while maintaining a high level of profitability in a challenging operating environment,” said Thierry Bernard, Chief Executive Officer of QIAGEN. “We achieved solid growth across key pillars, particularly Sample technologies, QIAcuity and QDI, while navigating continued pressure on instrument spending in the U.S. We are also building momentum behind important new product launches across our portfolio, in particular the rollout of new sample preparation systems and QIAcuity gene expression kits. This progress reinforces our confidence in stronger growth during the second half of 2026 and our focus on delivering solid profitable growth."
“Our adjusted operating income margin remained strong and improved from Q1 2026 while supporting targeted investments following the Parse acquisition and absorbing adverse currency headwinds,” said Roland Sackers, Chief Financial Officer of QIAGEN. “We increased the 2026 dividend by 40% compared with 2025 and continue to evaluate way to deploy capital to the highest-return opportunities. This performance reflects our continued focus on managing costs, prioritizing investments and generating an ongoing strong level of cash flow.”
Please find a PDF of the full press release incl. tables
here
.
Investor presentation and conference call
A conference call is scheduled for
Thursday, August 6, 2026, at 15:30 Frankfurt Time / 14:30 London Time / 9:30 New York Time.
A live audio webcast will be available in the Investor Relations section of the QIAGEN website (
www.qiagen.com
), with a recording accessible after the event. A presentation will be published in advance under "
Events and Presentations
" in the same section.
Use of adjusted results
QIAGEN reports adjusted results and constant exchange rate (CER) measures, along with other non-GAAP financial metrics, to provide deeper insight into business performance. These include adjusted gross margin and profit, adjusted operating income and expenses, adjusted operating income margin, adjusted net income, adjusted income before taxes, adjusted diluted EPS, adjusted tax rate, net leverage and free cash flow. Free cash flow is calculated as cash flow from operating activities less capital expenditures for property, plant and equipment. Adjusted results are non-GAAP measures that QIAGEN views as complementary to GAAP-reported results. They exclude items considered outside of ongoing core operations, subject to significant period-to-period fluctuation, or that reduce comparability with competitors and historical performance. QIAGEN also uses these non-GAAP and constant currency measures internally for planning, forecasting, reporting and employee compensation purposes. These metrics enable consistent comparison of current and past performance, which QIAGEN has historically presented on an adjusted basis.
QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of June 30, 2026, QIAGEN employed about 5,500 people across more than 35 locations. For more information, visit
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as “believe”, “hope”, “plan”, “intend”, “seek”, “may”, “will”, “could”, “should”, “would”, “expect”, “anticipate”, “estimate”, “continue”, “target” or other similar words. To the extent that any of the statements contained herein relating to QIAGEN’s products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. These include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and supply chain dependencies); variability of operating results; integration of acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN’s products (including fluctuations due to general economic conditions, the level and timing of customers’ funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN’s products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors’ products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” in our most recent Annual Report on Form 20-F. For further information, please refer to the QIAGEN's filings with the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Corporate
e-mail:
ir@QIAGEN.com
Public Relations
pr@QIAGEN.com
Twitter
Linked In
Facebook
Daniel Wendorff
Vice President
Head of Investor Relations
Germany
+49 2103 2911322
Mobile
+49 152 01811322
daniel.wendorff@qiagen.com
Download VCARD
Dr. Domenica Martorana
Associate Director Global Investor Relations
+49 2103 29 11244
+49 152 018 11244
domenica.martorana@qiagen.com
Alexandra Koenig
Investor Relations Coordinator
+49 2103 29 11709
+49 152 018 11709
alexandra.koenig@qiagen.com
Press Contacts
John Gilardi
Head of Corporate Communications
Germany:
+49 2103 29 11711
Mobile:
+49 152 018 11711
john.gilardi@qiagen.com
Lisa Specht
Manager Public Relations
Corporate Communications
+49-2103-29-14181
+49-152-018-11381
lisa.specht@qiagen.com
Jana Radoi
Corporate Communications Coordinator
+49 152 018 11670
jana.radoi@qiagen.com
Heeyoung Lee
Asia-Pacific region topics
South Korea:
+82 226265788
+82 01093389650
heeyoung.lee@qiagen.com
Natalia Silo
Latin America region topics
+55 11 98702 0137
natalia.silo@qiagen.com
To opt-in for investor email alerts, please enter your email address in the field below
and select at least one alert option. After submitting your request, you will receive an
activation email to the requested email address. You must click the activation link in
order to complete your subscription. You can sign up for additional alert options at any
time.
At QIAGEN N.V., we promise to treat your data with respect and will not share your
information with any third party. You can unsubscribe to any of the investor alerts you
are subscribed to by visiting the unsubscribe section below. If you experience any issues
with this process, please contact us for further assistance.
By providing your email address below, you are providing consent to QIAGEN N.V.
to send you the requested Investor Email Alert updates.
* Required
Um sich für E-Mail-Benachrichtigungen für Anleger anzumelden, geben Sie bitte
Ihre E-Mail-Adresse in das unten stehende Feld ein und wählen Sie mindestens eine
Benachrichtigungsoption aus. Nach dem Absenden Ihrer Anfrage erhalten Sie eine
Aktivierungs-E-Mail an die angegebene E-Mail-Adresse. Sie müssen den
Aktivierungslink anklicken, um Ihr Abonnement abzuschließen. Sie können sich
jederzeit für weitere Benachrichtigungsoptionen anmelden.
QIAGEN N.V. verpflichtet sich, Ihre Daten mit Respekt zu behandeln und sie nicht an
Dritte weiterzugeben. Sie können alle von Ihnen abonnierten Investor Alerts
abbestellen, indem Sie den unten stehenden Abschnitt "Abbestellen" besuchen. Sollten Sie
Probleme mit diesem Vorgang haben, wenden Sie sich bitte an uns, um weitere
Unterstützung zu erhalten.
Durch die Angabe Ihrer E-Mail-Adresse erklären Sie sich damit einverstanden,
dass QIAGEN N.V. Ihnen die angeforderten Investor Email Alert Updates
zusendet.
* Erforderlich
Email Address
*
Mailing Lists
Events
Presentations
SEC-Filings
End of Day Stock Quote
Unsubscribe
Abmelden
Email Alert Sign Up Confirmation
Anmeldebestätigung
E-Mail-Alarm
Follow Us
linkedin
open in new window
facebook
twitter
youtube
call back
mail
back to top
This site is protected by reCAPTCHA and the Google
Privacy Policy
and
Terms of Service
apply.
German
DISCLAIMER - IMPORTANT
ELECTRONIC VERSIONS OF THE MATERIALS YOU ARE SEEKING TO ACCESS ARE BEING MADE AVAILABLE ON THIS WEBPAGE BY QIAGEN IN GOOD FAITH AND FOR INFORMATION PURPOSES ONLY.
THESE MATERIALS ARE NOT DIRECTED AT OR ACCESSIBLE BY PERSONS LOCATED IN THE UNITED STATES OR TO U.S. PERSONS, AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR AUSTRALIA, JAPAN OR SOUTH AFRICA.
Please read this notice carefully, as it applies to all persons who view this webpage. Please note that the disclaimer set out below may be altered or updated. You should read it in full each time you visit the site.
Overseas Persons
Viewing the materials you seek to access may not be lawful in certain jurisdictions. In other jurisdictions, only certain categories of person may be allowed to view such materials. Any person who wishes to view these materials must first satisfy themselves that they are not subject to any local requirements that prohibit or restrict them from doing so.
In particular, unless otherwise determined by Qiagen and permitted by applicable law and regulation, it is not intended, subject to certain exceptions, that any offering of the securities mentioned in such materials (the "Securities") by Qiagen would be made, or any documentation be sent, directly or indirectly, in or into, the United States or to US persons, as defined in Regulation S under the Securities Act, or Australia, Japan, or South Africa.
These materials do not constitute or form a part of any offer or solicitation to purchase or subscribe for Securities in the United States or in any jurisdiction in which such offer or solicitation would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The Securities mentioned herein have not been and will not be registered under the Securities Act, and may not be offered, sold, resold, delivered or distributed, directly or indirectly, in or into United States except pursuant to an applicable exemption from the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States. There will be no public offering of, or solicitation to purchase, such Securities in the United States. The Securities mentioned herein will also not be registered under or offered in compliance with applicable securities laws of any state, province, territory, county or jurisdiction of Australia, Japan or South Africa. Accordingly, unless an exemption under the relevant securities law is applicable, any such Securities may not be offered, sold, resold, delivered or distributed, directly or indirectly, in or into Australia, Japan or South Africa or any other jurisdiction if to do so would constitute a violation of the relevant laws of, or require registration thereof in, such jurisdiction.
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are permitted to view these materials, please exit this webpage.
Basis of access
Access to electronic versions of these materials is being made available on this webpage by Qiagen in good faith and for information purposes only. Any person seeking access to this webpage represents and warrants to Qiagen that they are doing so for information purposes only. Making press announcements and other documents available in electronic format does not constitute an offer to sell or the solicitation of an offer to buy Securities in Qiagen. Further, it does not constitute a recommendation by Qiagen or any other party to sell or buy Securities in Qiagen.
Confirmation of understanding and acceptance of disclaimer
Electronic versions of these materials are not directed at or accessible by persons located in the United States or to U.S. persons, as defined in Regulation S under the Securities Act, or in Australia, Japan or South Africa or any other restricted jurisdiction.
By clicking on the “I Agree” button, I certify that I am not located in the United States and am not a U.S. person, nor am I located in Australia, Japan or South Africa or any other restricted jurisdiction.
I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the “I Agree” button, I confirm that I am permitted to proceed to electronic versions of these materials.
I Agree
Sample to Insight
© QIAGEN 2013-
. All rights reserved
Trademarks & Disclaimers
Site Map
Accessibility